The ANA Screen, IFA, Reflex Titer/Pattern, Panel 1 evaluates 25 analytes from a single sample to provide clear, positive identification of specific antibodies for the most common autoimmune rheumatic diseases.
This panel:
- Utilizes IFA with HEp-2 cells, which remains the gold standard3
- Tests for all analytes regardless of ANA results
- Tests for RA, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren's syndrome, systemic sclerosis (SSc), polymyositis/dermatomyositis, CREST syndrome, and neuropsychiatric SLE
The ANA, IFA, Cascade and Rheumatoid Arthritis Panel 2, with Reflexes from Quest Diagnostics provides clear, positive identification of specific antibodies for the 8 most common rheumatic diseases with 1 blood draw.
This panel:
- Utilizes IFA with HEp-2 cells, which remains the gold standard3
- Reflexes to tiered cascading of specific autoantibodies to maximize sensitivity and specificity
- Tests for RA, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren’s syndrome, systemic sclerosis (SSc), polymyositis/dermatomyositis, CREST syndrome, and neuropsychiatric SLE
RA and psoriatic arthritis can be difficult to diagnose clinically early in the disease process. MCV antibody, used in conjunction with rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody, may improve diagnostic sensitivity in the early diagnosis of RA.
Using 1 blood draw, our 13-antibody panel can help classify, evaluate, and differentially diagnose myositis. The inclusion of HMGCR and cN-1A antibodies aids in the diagnosis of more autoimmune myopathies than most standard panels. The autoantibodies included are Jo-1, cN-1A, HMGCR, PL-7, PL-12, EJ, OJ, SRP, Mi-2 Alpha, Mi-2 Beta, MDA-5, TIF-1y, NXP-2.
The Systemic Sclerosis (SSc) 12 Antibodies Panel 2 looks at several antibodies that are highly specific for SSc, including Scl-70, CENP-A, CENP-B, RP11, RP155, U1-snRNP RNP A, U1-snRNP RNP C, U1-snRNP RNP-70kd, fibrillarin, Th/To, PM/Scl-100, PM/Scl-75.
This panel:
- Helps to provide a diagnosis of SSc
- Helps physicians determine SSc type
- Identifies organ involvement
- Informs patient prognosis
- Looks at antibodies that are present in overlap syndromes with SSc
This test helps evaluate risk of severe cutaneous adverse reactions (SCARs) to allopurinol, which is widely used to treat conditions associated with hyperuricemia such as uric acid kidney stones, uric acid neuropathy during chemotherapy, and gout.
This panel evaluates 20 biomarkers to aid the diagnosis of connective tissue diseases (CTDs) that are associated with the development of interstitial lung disease (ILD), including rheumatoid arthritis, inflammatory myositis, systemic sclerosis, and Sjögren’s syndrome.
The Pre-biologic panel from Quest Diagnostics includes tests recommended by American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) guidelines for evaluating autoimmune patients prior to initiating therapy with biologics and/or biosimilars.
The panel includes tests for:
- HBV screening
- HCV screening
- TB infection screening with interferon gamma release assay (IGRA)
PrismRA is a blood-based, precision medicine, molecular signature response classifier (MSRC) that predicts inadequate response to TNFi therapy in RA. Patients with a molecular signature of inadequate response can be directed to a treatment with an alternative mechanism of action.
Adalimumab and Infliximab Testing
Quest Diagnostics offers testing that provides unique insights on patient response to tumor necrosis factor (TNF) blockers, so you can personalize treatment strategy for the best outcome. These tests measure TNF blocker drug levels and/or anti-drug antibodies in patients with rheumatic diseases such as RA, plaque psoriasis, and psoriatic arthritis.
